

Gary D Steinberg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9321188/gary-d-steinberg-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44
papers

1,134
citations

18
h-index

33
g-index

59
ext. papers

1,636
ext. citations

4.3
avg, IF

4.49
L-index

#	Paper	IF	Citations
44	Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter. <i>Bladder Cancer</i> , 2022 , 1-5	1	
43	Effect of neoadjuvant chemotherapy (NAC) on patient preferences for adjuvant treatment in muscle-invasive urothelial carcinoma (MIUC): A multi-country discrete choice experiment (DCE).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 454-454	2.2	
42	Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. <i>Journal of Urology</i> , 2021 , 101097JU0000000000002308	2.5	0
41	Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry. <i>BJU International</i> , 2021 ,	5.6	1
40	Editorial Comment. <i>Journal of Urology</i> , 2021 , 205, 1334	2.5	
39	Multi-step screening of neoantigensHLA- and TCR-interfaces improves prediction of survival. <i>Scientific Reports</i> , 2021 , 11, 9983	4.9	2
38	Editorial Comment. <i>Journal of Urology</i> , 2021 , 205, 1619-1620	2.5	
37	100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. <i>Nature Reviews Urology</i> , 2021 , 18, 611-622	5.5	19
36	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer 2021 , 9,		2
35	The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 436.e1-436.e8	2.8	2
34	Quality of Bladder Cancer Information on YouTube. <i>European Urology</i> , 2021 , 79, 56-59	10.2	10
33	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology, The</i> , 2021 , 22, 107-117	21.7	53
32	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. <i>Future Oncology</i> , 2021 , 17, 3137-3150	3.6	8
31	Non-muscle-invasive bladder cancer: An overview of potential new treatment options. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 642-663	2.8	6
30	KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. <i>Future Oncology</i> , 2020 , 16, 507-516	3.6	25
29	Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. <i>European Urology</i> , 2020 , 78, 387-399	10.2	11
28	Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. <i>European Urology</i> , 2020 , 78, 719-730	10.2	18

27	Editorial Comment. <i>Journal of Urology</i> , 2020 , 204, 987-988		2.5
26	Non-muscle-invasive Bladder Cancer: Overview and Contemporary Treatment Landscape of Neoadjuvant Chemoablative Therapies. <i>Reviews in Urology</i> , 2020 , 22, 43-51	1	6
25	Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 796.e1-796.e6	2.8	4
24	Update on the guideline of guidelines: non-muscle-invasive bladder cancer. <i>BJU International</i> , 2020 , 125, 197-205	5.6	31
23	ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. <i>Future Oncology</i> , 2020 , 16, 4359-4368	3.6	31
22	Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. <i>Human Pathology</i> , 2020 , 106, 54-61	3.7	2
21	Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018. <i>Nature Reviews Urology</i> , 2019 , 16, 377-386	5.5	30
20	Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy 2019 , 7, 66		30
19	Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage. <i>Current Urology Reports</i> , 2019 , 20, 84	2.9	24
18	Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 48-56	2.8	12
17	Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e12-e18	3.3	3
16	Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. <i>Journal of Urology</i> , 2018 , 199, 1158-1165	2.5	56
15	National Surgical Quality Improvement Program surgical risk calculator poorly predicts complications in patients undergoing radical cystectomy with urinary diversion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 77.e1-77.e7	2.8	16
14	An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 440-447	2.8	85
13	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. <i>European Urology Oncology</i> , 2018 , 1, 91-100	6.7	34
12	Re: Comparative Effectiveness of Fluorescent versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis: R. Chou, S. Selph, D. I. Buckley, R. Fu, J. C. Griffin, S. Grusing and J. L. Gore <i>J Urol</i> 2017;197:548-558. <i>Journal of Urology</i> , 2017 , 197, 1359-1360	2.5	
11	Utilization and Outcomes of Nephroureterectomy for Upper Tract Urothelial Carcinoma by Surgical Approach. <i>Journal of Endourology</i> , 2017 , 31, 661-665	2.7	28
10	Redefining the implications of nasogastric tube placement following radical cystectomy in the alvimopan era. <i>World Journal of Urology</i> , 2017 , 35, 625-631	4	8

9	Lessons from 151 ureteral reimplantations for postcystectomy ureteroenteric strictures: A single-center experience over a decade. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 112.e19-112.e25	2.8	11
8	Bladder cancer: Assessing the conundrum of microscopic haematuria. <i>Nature Reviews Urology</i> , 2016 , 13, 700-701	5.5	1
7	The effect of surgical approach on performance of lymphadenectomy and perioperative morbidity for radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 121.e15-21	2.8	26
6	Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. <i>Cancer Immunology Research</i> , 2016 , 4, 563-8	12.5	199
5	Medical management of patients with refractory carcinoma in situ of the bladder. <i>Drugs and Aging</i> , 2001 , 18, 335-44	4.7	13
4	New insights and candidate genes and their implications for care of patients with hereditary prostate cancer. <i>Current Urology Reports</i> , 2000 , 1, 9-14	2.9	1
3	EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER. <i>Journal of Urology</i> , 2000 , 163, 761-767	2.5	240
2	THE CURRENT STATUS OF BLADDER PRESERVATION IN THE TREATMENT OF MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2000 , 164, 627-632	2.5	42
1	The giant of the giant schwannomas. <i>Journal of Urology</i> , 1999 , 162, 791-2	2.5	4